The trial is being funded by medtech giant, Becton Dickinson.
Becton Dickinson is a major competitor to J&J in the breast reconstruction space.
The probability is now closer to 100% that SR teams up PNV with Ethicon (J&J) to do the same. I'd expect this news before Dec'2022. Yet another catalyst to ruin shorts. In the US markets, where small caps announce collaborations with majors, the sp goes vertical on the news... its even better when the major provides funding for trials
PNV - Banter and General Comments, page-8050
-
- There are more pages in this discussion • 4,994 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.07 |
Change
0.025(1.23%) |
Mkt cap ! $1.450B | |||
| Open | High | Low | Value | Volume |
| $2.11 | $2.12 | $2.06 | $2.023M | 967.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 11220 | $2.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.07 | 9143 | 29 |
View Market Depth
| Last trade - 15.09pm 08/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |